新辅助治疗后胰腺癌的处理方法:使用多层螺旋CT和肿瘤标志物评估可切除性
这项回顾性研究纳入179例非转移性胰腺癌患者,在新辅助化疗±放疗后采用多层螺旋CT评估可切除性分类,并分析CA19-9变化与R0切除的关联。新辅助治疗后CT可切除性分类与R0切除率显著相关,临界可切除组CA19-9下降≥50%及局部晚期组肿瘤≤2cm和肿瘤-动脉接触减少与R0切除相关。
要点
- 新辅助治疗后CT可切除性分类为可切除、临界可切除、局部晚期时,R0切除率分别为82.8%、70.1%、18.5%(p<0.001)。
- 新辅助治疗后临界可切除病变中,CA19-9下降≥50%与R0切除显著相关(OR 3.160;p=0.02)。
- 新辅助治疗后局部晚期病变中,肿瘤≤2cm(OR 9.668)和肿瘤-动脉接触减少(OR 24.213)与R0切除相关。
核心结论
- 新辅助放化疗后多层螺旋CT可切除性分类可能有助于评估胰腺癌患者的R0可切除性;临界可切除病变中CA19-9下降≥50%与R0切除相关,局部晚期病变中肿瘤≤2cm和肿瘤-动脉接触减少与R0切除相关。
研究设计与样本
- 回顾性研究,纳入2009年6月至2019年6月期间接受新辅助化疗±放疗的连续非转移性胰腺癌患者179例(平均年龄62.4±9.3岁;92例男性),在基线和放化疗后行多层螺旋CT评估肿瘤大小、肿瘤-血管接触及局部可切除性分类,并检测基线和放化疗后CA19-9水平,采用逻辑回归分析确定与R0切除相关的临床或影像特征。
诊断标准与关键数值
- 放化疗后CT可切除性分类为可切除、临界可切除、局部晚期时,R0切除率分别为82.8%(48/58)、70.1%(47/67)、18.5%(10/54),三组间差异显著(p<0.001);放化疗后临界可切除病变中CA19-9下降≥50%与R0切除相关(OR 3.160;p=0.02);放化疗后局部晚期病变中肿瘤≤2cm(OR 9.668;p=0.026)和肿瘤-动脉接触减少(OR 24.213;p=0.022)与R0切除相关。
临床应用与阅片要点
- 新辅助放化疗后应行多层螺旋CT评估可切除性分类,并结合CA19-9变化及肿瘤大小、肿瘤-动脉接触变化综合判断R0切除可能性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate clinical and CT factors associated with local resectability in patients with nonmetastatic pancreatic cancers after neoadjuvant chemotherapy ± radiation therapy (CRT).
METHODS: This retrospective study included consecutive patients with nonmetastatic pancreatic cancers who underwent neoadjuvant CRT between June 2009 and June 2019. Tumor size, tumor-vascular contact with artery/vein, and local resectability categories (resectable, borderline resectable, or locally advanced) were assessed at baseline and post-CRT CT. Baseline and post-CRT carbohydrate antigen (CA) 19-9 levels were also assessed. Clinical or imaging features related to R0 resection were determined using logistic regression analysis.
RESULTS: A total of 179 patients (mean age, 62.4 ± 9.3 years; 92 men) were included. After neoadjuvant CRT, 105 (58.7%) patients received R0 resection, while 74 (41.3%) did not. R0 resection rates were significantly different according to post-CRT CT resectability categories (p < 0.001): 82.8% (48/58), 70.1% (47/67), and 18.5% (10/54) for resectable, borderline resectable, and locally advanced disease, respectively. For post-CRT borderline resectable disease, ≥ 50% decrease in CA 19-9 was significantly associated with R0 resection (odds ratio (OR), 3.160; p = 0.02). For post-CRT locally advanced disease, small post-CRT tumor size ≤ 2 cm (OR, 9.668; p = 0.026) and decreased tumor-arterial contact (OR, 24.213; p = 0.022) were significantly associated with R0 resection.
CONCLUSION: Post-CRT CT resectability categorization may be useful for the assessment of R0 resectability in patients with pancreatic cancer following neoadjuvant CRT. Additionally, ≥ 50% decrease in CA 19-9 was associated with R0 resection in post-CRT borderline resectable disease, while small post-CRT tumor size and decreased tumor-arterial contact were with locally advanced disease.
KEY POINTS: • R0 resection rates following neoadjuvant chemotherapy ± radiation therapy (CRT) were 82.8%, 70.1%, and 18.5% in resectable, borderline resectable, and locally advanced disease, respectively, at post-CRT CT (p < 0.001). • For post-CRT borderline resectable disease, ≥ 50% decrease in carbohydrate antigen (CA) 19-9 was significantly associated with R0 resection. • For post-CRT locally advanced disease, small post-CRT tumor size ≤ 2 cm and decreased tumor-arterial contact were significantly associated with R0 resection.
引用
- Jeon SK, Lee JM, Lee ES, et al. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers. Eur Radiol. 2021. PMID: 34170366. doi:10.1007/s00330-021-08108-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。